Additional Supporting Information may be found in the online version of this article.

HEP_23882_sm_suppfig1.tif2143KSupporting Figure 1. Cell proliferation in primary Stat5+/+ and Stat5-/- MEFs. (A) Cell growth curve of MEFs. Cell viability was determined in Stat5+/+ and Stat5-/- MEFs at the 13th and 16th passage. All values represent means ± SD from 3 independent experiments. **P < .01 compared with corresponding controls.
HEP_23882_sm_suppfig2.tif7955KSupporting Figure 2. Histological analyses of liver tissue from Stat5f/f and Stat5f/f; Alb-Cre mice. (A) Hematoxylin and eosin (H&E) staining of liver sections from STAT5f/f and STAT5f/f;Alb-Cre mice. (B) H&E staining of liver sections from Stat5f/f and Stat5f/f; Alb-Cre mice injected with CCl4 for 12 weeks. In the absence of CCl4, hepatosteatosis was observed only in liver-specific STAT5-null mice (panel A). Exacerbated fat accumulation (arrows) was observed in liver-specific STAT5-null mice upon CCl4 treatment.
HEP_23882_sm_suppfig3.tif7570KSupporting Figure 3. Development of HCC in CCl4-injected Stat5f/f; Alb-Cre mice. (A) Liver of Stat5f/f and Stat5f/f;Alb-Cre mice after 12 weeks of CCl4 injection. (B) Tumor multiplicity, (C) size and (D) incidence in livers of Stat5f/f;Alb-Cre mice that were given CCl4 for 12 weeks. All values represent means ± SD (n = 8-10).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.